Both Sides Lay Cards on The Table on Drug Pricing

July 9, 2021 by Dan McCue
Both Sides Lay Cards on The Table on Drug Pricing
Pharmaceuticals are seen in North Andover, Mass.(AP Photo/Elise Amendola, file)

WASHINGTON – A trio of House Democrats, including House Speaker Nancy Pelosi, D-Calif., and Rep. Carolyn Maloney, D-N.Y., chair of the House Committee on Oversight and Reform, accused the nation’s largest pharmaceutical companies on Thursday of being more concerned with “self enrichment” than in the well-being of the customers who rely on them for prescription drugs.

Joined at a mid-afternoon press conference by Rep. Peter Welch, D-Vt., and patient advocates, the Democrats based their attacks on the industry on a new report, the seventh Maloney’s committee has issued on drug prices since it began investigating the issue 2 ½ years ago.

The findings of the latest report, Maloney said, are based on an analysis of the financial data of the 14 largest drug companies in the world.

What the committee found, the Democrats said, is that the leading drug companies have routinely spent more on stock buybacks, dividends to investors, and executive compensation than on research and development.


“This analysis also reveals that drug companies’ claims that reducing U.S. prescription drug prices will harm innovation is overblown,” Maloney said.

The participating members of Congress are pushing hard for the passage of H.R. 3, the Elijah E. Cummings Lower Drug Prices Now Act, which, among other things, empowers Medicare to negotiate directly with drug companies to lower prices. 

The press conference came at a time when Democrats appear committed to passing some form of legislation this year curbing prescription drug prices, but disagree considerably on the details.

The Congressional Budget Office has estimated that H.R. 3’s negotiation provisions would save taxpayers $456 billion over 10 years, Pelosi said.

She went on to assure reporters on the conference call that even with the Act in place, drug companies could maintain or even exceed their current research and development expenditures, if only they were willing to reduce their spending on buybacks, dividends and executive pay.


Pelosi said she plans to push the legislation through the House by budget reconciliation, which would mean it could pass the Senate without Republican backing.

In response Brian Newell, a spokesman for industry association PhRMA, said while the organization couldn’t speak to the specific examples cited in the report, “this partisan exercise is clearly designed to garner support for an extreme bill that will erode Medicare protections and access to treatments for seniors.” 

According to the report, between 2016 and 2020, the 14 companies under the microscope spent $577 billion on stock buybacks and dividends — $56 billion more than they spent on research and development during the same period.

“One company, Amgen, spent nearly six times as much on buybacks, dividends, and executive compensation as it did on R&D in 2018,” said Welch.

Meanwhile, the Democrats reported, from 2016 to 2020, compensation for the 14 companies’ top executives totaled $3.2 billion, with annual compensation growing by 14% over that five-year period. 

Some companies paid their CEOs tens of millions of dollars as they raised prices on drugs relied on by millions of Americans, Pelosi said. At the same time, the Democrats concluded, many of these companies actively sought to suppress generic and biosimilar competition “while continuing to raise prices.”

But PhRMA’s Newell begged to differ.

“Every year, biopharmaceutical research companies invest tens of billions of dollars in the research and development of new cures and treatments, as well as our significant investments in time and resources creating treatments and vaccines to combat the global pandemic,” he said.


“Nonpartisan experts have highlighted the fact that net prices for medicines are trending down while patients continue to struggle with high deductibles and other out-of-pocket costs. 

“We have put forward ideas that would lower costs at the pharmacy, while preserving choice, access and innovation. We are committed to working with policymakers on commonsense, bipartisan solutions that address the real challenges patients face. Working together we can make sure medicines are affordable and accessible for everyone,” Newell added.

A+
a-

In The News

Health

Voting

Prescription Drugs

Pfizer Buying Spree Continues With $5.4B Hematology Deal

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of... Read More

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic. Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets... Read More

Over-the-Counter Birth Control? Drugmaker Seeks FDA Approval

WASHINGTON (AP) — For the first time, a pharmaceutical company has asked for permission to sell a birth control pill... Read More

WASHINGTON (AP) — For the first time, a pharmaceutical company has asked for permission to sell a birth control pill over the counter in the U.S. HRA Pharma’s application on Monday sets up a high-stakes decision for health regulators amid legal and political battles over women’s... Read More

July 8, 2022
by Natalie McCormick
Overturning Roe Has Birth Control and Emergency Contraceptives in High Demand

WASHINGTON — In the wake of the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization, which overturned Roe... Read More

WASHINGTON — In the wake of the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization, which overturned Roe v. Wade, demand for various forms of contraceptives, including the so-called morning-after pill, and long-lasting forms of birth control, has surged.  Doctors, women’s health clinics and... Read More

July 5, 2022
by Tom Ramstack
Drug Distributors Win Lawsuit Accusing Them of Opioid Abuse

CABELL COUNTY, W.Va. — A federal judge in West Virginia on Monday ruled in favor of drug distribution companies accused... Read More

CABELL COUNTY, W.Va. — A federal judge in West Virginia on Monday ruled in favor of drug distribution companies accused in a lawsuit of creating a public nuisance by distributing opioids that kill thousands of Americans each year. The judge said his ruling is "not based... Read More

April 27, 2022
by Tom Ramstack
Lawmakers Say Consulting Firm Marketing Contributed to Half-Million Opioid Deaths

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the... Read More

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the opioid epidemic that has killed more than a half-million Americans. A McKinsey & Co. official admitted to earning at least $86 million for helping pharmaceutical companies... Read More

April 19, 2022
by Dan McCue
Supreme Court Seeks Solicitor General Input on Biologic Drug Patents

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent... Read More

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent case the outcome of which could ultimately be worth billions of dollars. The case, Amgen v. Sanofi, emanates from the U.S. District Court for the Federal... Read More

News From The Well
scroll top